Results from the KEYNOTE-522 trial showed that adding pembrolizumab to neoadjuvant chemotherapy and as adjuvant therapy increased the rates of pathologic complete response (pCR) in patients with stage 3 and/or node-positive early triple-negative breast cancer. The benefit of neoadjuvant pembrolizumab + chemotherapy on pCR was also observed in patients who received less than the planned chemotherapy (although absolute pCR rates were lower), and regardless of combined positive score threshold.
Results from the phase 1b KEYNOTE-173 and the phase 2 I-SPY 2 studies already demonstrated that the combination of pembrolizumab with chemotherapy as neoadjuvant treatment had manageable side effects and promising anti-tumour activity in patients with locally advanced triple-negative breast cancer [1,2]. The phase 3 KEYNOTE-522 study assessed pembrolizumab + chemotherapy (n=401) versus placebo + chemotherapy (n=201) as neoadjuvant therapy, followed by pembrolizumab ver...
Please login to read the full text of the article.
If you have no account yet, please register now.
« HER2 antibody-drug conjugate T-DXd promising in T-DM1 pretreated patients Next Article
Breast cancer incidence decreased by oestrogen alone but increased by adding progestin »